| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 6
| Issue : 3 | Page : 145-151 |
|
|
A link among schizophrenia, diabetes, and asthma: Role of Ca2+/cAMP signaling
Leandro Bueno Bergantin
Department of Pharmacology, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
Correspondence Address:
Leandro Bueno Bergantin
Department of Pharmacology, Escola Paulista School of Medicine, Federal University of São Paulo, Rua Pedro De Toledo, 669, Vila Clementino, São Paulo
Brazil
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/bc.bc_66_19
|
|
|
Asthma has been associated with an increased risk for developing schizophrenia. In addition, schizophrenia has been associated with an increased risk for developing type 2 diabetes mellitus, resulting in an elevated cardiovascular risk and in a limited life expectancy. It is well discussed that dysregulations related to Ca2+ signaling could link these diseases, in addition to cAMP signaling pathways. Thus, revealing this interplay among schizophrenia, diabetes, and asthma may provide novel insights into the pathogenesis of these diseases. Publications involving Ca2+ and cAMP signaling pathways, schizophrenia, diabetes, and asthma (alone or combined) were collected by searching PubMed and EMBASE. Both Ca2+ and cAMP signaling pathways (Ca2+/cAMP signaling) control the release of neurotransmitters and hormones, in addition to airway smooth muscle contractility, then dysregulations of these cellular processes may be involved in these diseases. Taking into consideration, the experience of our group in this field, this narrative review debated the involvement of Ca2+/cAMP signaling in this link among schizophrenia, diabetes, and asthma, including its pharmacological implications.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
